Jing Wang

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 533 citations · Full text

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

Kaiming Sun, Keith Mikule, Zebin Wang et al. · Oncotarget · 2018 · 177 citations · Full text

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer

Ning Li, Jianqing Zhu, Rutie Yin et al. · JAMA Oncology · 2023 · 143 citations · Full text

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer

Jason P.W. Carey, Cansu Karakaş, Tuyen Bui et al. · Cancer Research · 2017 · 140 citations · Full text

Breast Oncology, Synthetic Lethality, Cancer Biology +19

FBXW7 alleviates hyperglycemia-induced endothelial oxidative stress injury via ROS and PARP inhibition

Shenping Li, Junjie Deng, Dandan Sun et al. · Redox Biology · 2022 · 72 citations · Full text